Axa S.A. Immunome Inc. Call Options Transaction History
Axa S.A.
- $33.6 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMNM
# of Institutions
150Shares Held
66.6MCall Options Held
44.9KPut Options Held
4.24M-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.28MShares$133 Million0.05% of portfolio
-
Redmile Group, LLC San Francisco, CA4.87MShares$78.3 Million5.51% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.69MShares$75.3 Million0.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.52MShares$72.7 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.08MShares$65.6 Million3.27% of portfolio
About Immunome Inc.
- Ticker IMNM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,127,400
- Market Cap $195M
- Description
- Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...